Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

167.02 -3.86 (-2.26%)
Streaming Delayed Price Updated: 12:24 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Charles River Laboratories International, Inc. Common Stock

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
From Charles River Laboratories International, Inc.
Via Business Wire
Virpax Posts Toxicology, Pharmacokinetic Data For Pain Med Epoladerm
Virpax Pharmaceuticals Inc (NASDAQ: VRPX) reported results following toxicology and pharmacokinetic study of Epoladerm to manage pain associated with... 
Via Benzinga
Charles River Laboratories to Participate in Upcoming Investor Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Promotes Birgit Girshick to Chief Operating Officer
From Charles River Laboratories International, Inc.
Via Business Wire
Stocks That Hit 52-Week Highs On Thursday
Thursday's morning session saw 167 companies set new 52-week highs. Points of Interest: ASML Holding (NASDAQ:ASML) was the largest company by market cap to set a new... 
Via Benzinga
Where Charles River Stands With Analysts
Charles River (NYSE:CRL) has observed the following analyst ... 
Via Benzinga
Charles River Laboratories International, inc (CRL) Q3 2021 Earnings Call Transcript
CRL earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Why Charles River Laboratories International Shares Dropped 16.7% This Week
The company's stock dropped nearly $75 a share over the course of the week, rattling investors. 
Via The Motley Fool
Charles River Posts Mixed Q3 Earnings; Narrows FY21 EPS Guidance
Charles River Laboratories International Inc (NYSE: CRL) Q3 sales increased 20.5% Y/Y to $895.9 million, missing the consensus of $903.20 million. Acquisitions... 
Via Benzinga
Charles River Laboratories Announces Third-Quarter 2021 Results
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Plans to Increase CRADL Capacity in Cambridge
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and ATEM Structural Discovery Announce Strategic Partnership to Provide Clients with Cryo-EM Capabilities
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Schedules Third-Quarter 2021 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Announces Two Divestitures
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Launches First Annual Healthcare Collaboration Report
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Participate in September Investor Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
You Won't Believe the Risk This Healthcare Company Faces
It's older than the dinosaurs. 
Via The Motley Fool
Stocks That Hit 52-Week Highs On Monday
Before 10 a.m. ET on Monday, 119 companies hit new 52-week highs. Noteables: The largest company by market cap to set a new 52-week high was Alphabet (NASDAQ:GOOG... 
Via Benzinga
Stocks That Hit 52-Week Highs On Friday
Before 10 a.m. ET on Friday, 52 companies hit new 52-week highs. Highlights: Microsoft (NASDAQ:MSFT) was the biggest company by market cap to set a new 52-week high... 
Via Benzinga
Illumina Stock Earns Membership In Elite Club
Illumina saw its IBD SmartSelect Composite Rating rise to 97 Tuesday, up from 93 the day before. 
Via Investor's Business Daily
Medpace Stock Shows Rising Price Performance With Jump To 83 RS Rating
Medpace sees its Relative Strength Rating reach the 80-plus level. 
Via Investor's Business Daily
How Does Charles River's Debt Look?
Shares of Charles River (NYSE:CRL) rose by 27.14% in the past three months. Before having a look at the importance of debt, let us look at how much debt Charles River has.... 
Via Benzinga
Charles River Laboratories International, inc (CRL) Q2 2021 Earnings Call Transcript
CRL earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Recap: Charles River Q2 Earnings
Shares of Charles River (NYSE:CRL) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share increased 65.19% year over year to $2.61,... 
Via Benzinga
Charles River Laboratories Announces Second-Quarter 2021 Results
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Schedules Second-Quarter 2021 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
10 Top-Ranked Stocks Powering S&P 500 ETF
Though most stocks in the fund’s portfolio have been in the deeper green so far this year, here are 10 stocks that led the rally. 
Via Talk Markets
Topics Stocks
Charles River Laboratories Completes Acquisition of Vigene Biosciences
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River's Jim Foster Beat The Trauma Of Being CEO
Think taking over the family business is easy? Charles River CEO Jim Foster might beg to differ. He's shown that being CEO comes with trauma. 
Via Investor's Business Daily
Stocks That Hit 52-Week Highs On Thursday
This morning 94 companies set new 52-week highs. Things to Consider: NVIDIA (NASDAQ:NVDA) was the largest firm by market cap to set a new 52-week high. Deswell Industries... 
Via Benzinga
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.